PRXL2C

Across TCGA pan-cancer cohorts, PRXL2C Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PRXL2C data layer compared with 23 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher PRXL2C Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PRXL2C expression acts as an unfavorable survival marker.

STAD, SARC, and ESCA are the cancer types where PRXL2C Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	All	0.003	0.688	<.001	36	view →
SARC	DFS	Median	All	0.121	0.611	.041	6	view →
ESCA	OS	Median	II,III,IV	0.216	0.702	.014	6	view →
COAD	OS	Median	III,IV	0.140	0.691	.017	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PRXL2C–STAD (OS)

Open the STAD breakdown →